Experiences with
Crizotinib34 public posts
Want to take advantage of all our features? Just log in!
or
FDA Updates Approval for Lobrena to First Line Treatment for Advanced NSCLC Patients with Changes in ALK
The FDA based their approval on the results of a clinical trial which found that patients receiving Lobrena went longer before experiencing progression than those who received Xalkori (crizotinib).
FDA Approves Brigatinib for ALK-positive Metastatic NSCLC
The FDA based their approval on the results of the clinical trial ALTA 1L which showed that patients receiving Alunbrig (brigatinib) had a higher chance of responding well to treatment, and went longer periods of time without progression than those receiving Xalkori (crizotinib).
Stopping Braftovi Mektovi targeted medications
It has been shown that the crizotinib induces alterations in the secretome of the melanoma cells contributing to the emergence and expansion of the resistant subpopulations [86].
Drug Submission time again. We are looking to speak to anyone who has experience of Loratinib (Lorviqua)
will be assessed under is: "As monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: Alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or Crizotinib